(Q37812612)

23 August 2017

0 references

Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies (English)

1 reference

23 August 2017

1 reference

Marc Colombel

2

0 references

Fred Saad

series ordinal

1

object named as

Fred Saad

1 reference

23 August 2017

language of work or name

1 reference

1 December 2010

1 reference

Expert Review of Anticancer Therapy

23 August 2017

published in

1 reference

23 August 2017

volume

10

1 reference

23 August 2017

issue

12

1 reference

23 August 2017

page(s)

1991-2002

1 reference

Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Natural history and treatment of bone complications in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic Acid in patients with bone metastases from solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

New research findings on zoledronic acid: survival, pain, and anti-tumour effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Risks and benefits of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Significance and impact of bisphosphonate-induced acute phase responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Recommendations for zoledronic acid treatment of patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Zoledronic acid: a review of its use in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Safety profile of intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Src as a therapeutic target in men with prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Update: immunological strategies for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.191

21 January 2018

Identifiers

DOI

10.1586/ERA.10.191

1 reference

23 August 2017

1 reference